EMRELIS
Telisotuzumab Vedotin
- Strength
- 100 mg/mL
- Form
- Injection, Powder, Lyophilized, For Solution
AbbVie Inc.
Not stocked by us — reference only
Telisotuzumab Vedotin
Listed by AbbVie Inc.
| Dosage form | Injection, Powder, Lyophilized, For Solution |
|---|---|
| Route | Intravenous |
| Approval route | BLA — biologic licence |
| NDC code | 0074-1044 |
| FDA application | BLA761384 |
| RxNorm concept | 2714245 |
| Package sizes listed | 1 |
| Marketed since | May 2025 |
Same active ingredient, different manufacturer, strength or form. Products matching on both ingredient and strength are usually interchangeable — but confirm before switching, especially with modified-release forms.
Telisotuzumab Vedotin
AbbVie Inc.
Not stocked by us — reference only
Information only, not medical advice. Nothing on this page indicates that a medication is safe or suitable for you. Speak to a prescriber or pharmacist before starting, stopping or switching any medicine.
Please don't share card details in chat.